Changchun Hi-Tech (000661.SZ) subsidiary Fuxinqibizumab injection is newly included in the national medical insurance catalogue

Zhitongcaijing · 1d ago

According to the Zhitong Finance App, Changchun Hi-Tech (000661.SZ) announced that Jin Beixin (generic name “fuxin qibizumab injection”) independently developed by the company's holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”) has been newly included in the national medical insurance catalogue. Jin Beixin (fuxinqibimab) is a novel all-human anti-IL-1beta monoclonal antibody drug developed by Jinsai Pharmaceutical. It is a class 1 new drug for therapeutic biological products. It can specifically bind human IL-1β to block the production of inflammatory mediators induced by IL-1beta, and is used in adult patients with acute attacks of gout arthritis.